Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Agios Pharmaceuticals (AGIO) over the last 5 years, with Q3 2025 value amounting to $802.5 million.

  • Agios Pharmaceuticals' Treasury Shares changed 0.0% to $802.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $802.5 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $802.5 million for FY2024, which is 0.0% changed from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Treasury Shares stood at $16.2 million, which was down 9990.0% from $16.2 million recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Treasury Shares peaked at $16.2 billion during Q1 2022, and registered a low of $7.1 million during Q1 2021.
  • Over the past 5 years, Agios Pharmaceuticals' median Treasury Shares value was $16.2 billion (recorded in 2022), while the average stood at $9.9 billion.
  • Examining YoY changes over the last 5 years, Agios Pharmaceuticals' Treasury Shares showed a top increase of 5168.52% in 2022 and a maximum decrease of 0.0% in 2022.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Treasury Shares stood at $802.5 million in 2021, then changed by 0.0% to $802.5 million in 2022, then changed by 0.0% to $802.5 million in 2023, then changed by 0.0% to $802.5 million in 2024, then changed by 0.0% to $802.5 million in 2025.
  • Its Treasury Shares was $802.5 million in Q3 2025, compared to $802.5 million in Q2 2025 and $802.5 million in Q1 2025.